JUBILANT BIOSYS (BVI) LTD Balance Sheet

As at 31st Mar	Notes No	2014	2014	2013	2013
		USD	INR (' In Thousands)	USD	INR (' In Thousands)
I. EQUITY AND LIABILITIES Shareholders' Funds					
Share capital		1,397,501	69,846	1,377,501	68,772
Reserves & surplus	2	(22,877)	12,507	(18,349)	5,016
		1,374,624	82,354	1,359,152	73,788
Current liabilities "" " Current liabilities " " " Current liabilities " " " " " " " " " " " " " " " " " " "	skationepiante distibute infin	d manufacture of the property and the	-properties and the company of the con-	same and and and a significant	man militariya ya iyo isanii yi iyo giribi a c
Trade payables	3	1,280	77	-	-
Other current liabilities	4	-	-	579	31
		1,280	77	579	31
	Total				1.50
		1,375,904	82,430	1,359,731	73,820
II. ASSETS		7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7			
Non-current investments	5	1,371,501	82,167	1,356,501	73,644
		1,371,501	82,167	1,356,501	73,644
Current assets					N. 35
Cash & bank balances	6	4,174	250	3,004	163
Short-term loans and advances	7	229	14	226	12
		4,403	264	3,230	175
	Total	1,375,904	82,430	1,359,731	73,820

Rajneesh Gupta Head Accounts Place: Noida Date: 22nd May 2014

JUBILANT BIOSYS (BVI) LTD Statement of Profit and Loss

For the year ended 31st March, Notes No	2014	2014	2013	2013
	USD	INR (' In Thousands)	USD	INR (' In Thousands)
EXPENSES				
Other expenses 8	4,527	274	4,427	241
Total expenses	4,527	274	4,427	241
Profit for the Year	(4,527)	(274)	(4,427)	(241)

Rajneesh Gupta Head Accounts Place: Noida Date: 22nd May 2014

JUBILANT BIOSYS (BVI) LTD

CACH FLOW CTATEMENT

For the year ended 31st March,	2014	2014	2013	2013
	USD	INR (' In Thousands)	USD	INR (' In Thousands)
A. Cash flows from operating activities				
Net income before minority interest	(4,527)	(274)	(4,427)	(241)
Operating profit before working capital changes	(4,527)	(274)	(4,427)	(241)
Adjustments for:				
(Increase)/Decrease in trade and other receivables	(3)	(0)	1,299	71
Increase/(Decrease) in trade and other payables	701	42	579	31
Net cash inflow/(outflow) in course of operating activities	(3,829)	(232)	(2,548)	(139)
	weeks to be a second and the second	micanicanistration and the	Anaming ang panggalang kanggalang an	Colopolis del Managerich Colopolis de la Colop
B. Cash flow arising from investing activities:				
(Purchase)/sale of investments (net)(Including in Subsidiaries)	(15,000)	(906)	(5,500)	(299)
Net cash inflow/(outflow) in course of investing activities	(15,000)	(906)	(5,500)	(299)
C. Cash flow arising from financing activities:				
Proceeds from issue of share capital(including share premium & net of share issue expenses)	20,000	1,208	5,500	299
Net cash inflow/(outflow) in course of financing activities	20,000	1,208	5,500	299
D. Foreign currency translation difference arising on consolidation		17		19
Net Increase in cash & cash equivalents (A+B+C+D)	1,171	87	(2,548)	(119)
All to Construct the All to Construct the Construction of the Cons				
Add: cash & cash equivalents at the beginning of year (including balance in dividend accounts)	3,004	163	5,553	282
Cash & cash equivalents at the close of the year(including balance in dividend accounts)	4,175	250	3,004	163

Notes:

Rajneesh Gupta Head Accounts Place: Noida

Date: 22nd May, 2014

¹⁾ Cash Flow Statement has been prepared under the indirect method as set out in the Accounting Standard 3 (AS-3)-" Cash Flow Statements".

JUBILANT BIOSYS (BVI) LTD

Notes to the Financial Statements

As at 31st Mar	2014	2014	2013	2013
Particulars	USD	INR (' In Thousands)	USD	INR (' In Thousands)
1. SHARE CAPITAL				
Authorized 10,000,000 equity shares of USD 1 each				
Preference share capital	in somstannes decleristististististis	vidajāvies eksterājas kar aptadājā das	More and the Mark and the American Security	kutijast jilv riteaja je dja čemisk decele
(Previous Year 10,000,000 equity shares of USD 1 each)	-	-	-	•
adalaminten terminan an kangalamin di manah mendilamin kan di manah mendilaminten di mendilami bahagi mendilam Kanad O Cabarathad			Contra province province	
Issued & Subscribed 1,377,501 equity shares of USD 1 each				
Preference share capital	-	-	-	-
(Previous Year 1,397,501 equity shares of USD 1 each)	-	-	-	-
Paid up 1,397,501 equity shares of USD 1 each	1,397,501	69,846	1,377,501	68,772
(Previous Year 1,377,501 equity shares of USD 1 each)	1,557,501	05,540	1,517,501	00,772
	1,397,501	69,846	1,377,501	68,772

- 1) The Company has only one class of shares referred to as equity shares having no par value. Each holder of equity shares is entitled to one vote per share.
- 2) In the event of liquidation of the Company, the holders of equity shares will be entitled to receive any of the remaining assets of the Company, after distribution of all preferential amounts, if any, in proportion of their shareholding. However, no such preferential amounts exist currently.
- 3) The details of shareholders holding more than 5% shares in the company:

As at 31st Mar	2014	2014	2013	2013
Name of the shareholder	No of shares	% held	No of shares	% held
Jubilant Life Sciences (BVI) Ltd., British Virgin Islands - the Holding Company	1,397,501	100%	1,377,501	100%

4) The reconcilations of number of shares outstanding at beginning and at the end of reporting period

As at 31st Mar	2014	2014	2013	2013
Particulars	No	INR (' In Thousands)	No	INR (' In Thousands)
Numbers of shares at the beginning	1,377,501	68,772	1,372,001	68,466
Add: Shares issued during the year	20,000	1,074	5,500	306
Numbers of shares at the end	1,397,501	69,846	1,377,501	68,772

5) Shares held by holding company/ultimate holding company and/or their subsidiaries/associates
Out of the equity Shares issued by the company, shares held by it's holding company/ultimate holding company and/or their subsidiaries/associates are as below:

As at 31st Mar	2014	2014	2013	2013
Particulars	No	INR (' in Thousands)	No	INR (' In Thousands)
Jubilant Life Sciences (BVI) Ltd., British Virgin Islands - the Holding Company	1,397,501	69,846	1,377,501	68,772
1,377,501 equity shares of USD 1 each				
(Previous Year 1,397,501 equity shares of USD 1 each)			The State State of the State	

JUBILANT BIOSYS (BVI) LTD

Notes to the Financial Statements

As at 31st Mar	2014	2014	2013	2013
	USD	INR (' In Thousands)	USD	INR (' In Thousands)
2. RESERVES AND SURPLUS				
Foreign Currency Translation Reserve			5.4 (1.4 %)	
Foreign Currency Transalation Reserve Opening	and the second s	5,908	and the second s	1,277
Foreign Currency Transalation Reserve During the Year	error er	7,766	-	4,631
		13,674	_	5,908
Surplus as per P&L Account	energia de la composição	entrafed stripts of beneather the proper		
As per last Balance Sheet	(18,350)	(892)	(13,922)	(651
Add: Net Profit after tax transferred from Statement of Profit and Loss	(4,527)	(274)	(4,427)	(241
	(22,877)	12,507	(18,349)	5,016
3. TRADE PAYABLES	. 그 그를 그런 얼마지않			
Trade payables-others	1,280	77	<u>-</u>	
	1,280	77	-	-
4. OTHER CURRENT LIABILITIES				
Other payables		-	579	31
	-	- 1	579	31
그렇게요! 하는 사람이는 하는데 말은 것 하는 하는 수 있는데 하는데 없다.				
5. NON-CURRENT INVESTMENTS				
Investment in Subsidiary/ Fellow subsidiaries Companies			The Market Market Market	
Jubilant Biosys (Singapore) PTE Ltd	1,371,501	82,167	1,356,501	73,644
1,371,501 shares (previous year 1,356,501 shares) of USD 1 each			14.87.17	
	1,371,501	82,167	1,356,501	73,644
	그리 이 시 하는 밝혔			
5. CASH AND BANK BALANCES				
Cash and cash equivalents				\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \
Balances with banks:		3.3 4.4 5.1 2.2		
- On current accounts	4,174	250	3,004	163
	4,174	250	3,004	163
	문입하는데 그 사람들은 살아보다			
7. SHORT TERM LOANS AND ADVANCES				
Control of the second of the s	229	14	226	12
	229	14	226	12
도양 경험 경험 하는 사람들이 얼마는 것이 없는 것이 없는 것이 없는 것이 없다.				
3. OTHER EXPENSE	지나 시간에 보고 있었다면서			
egal, professional & consultancy charges	4,427	268	4,347	236
Bank Charges	100	6	80	4
	4,527	274	4,427	241